Report cover image

Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Research Report 2025(Status and Outlook)

Publisher Bosson Research
Published Jul 02, 2025
Length 171 Pages
SKU # BOSS20194186

Description

Report Overview

Neurological biomarkers for Alzheimer's and Parkinson's diseases are measurable biological indicators that aid in the early detection, diagnosis, and monitoring of these neurodegenerative disorders. These biomarkers include proteins (e.g., amyloid-beta, tau, alpha-synuclein), genetic markers, cerebrospinal fluid (CSF) analytes, neuroimaging signals (e.g., PET scans, MRI), and blood-based markers. Their role is critical in differentiating between disease subtypes, assessing progression, and evaluating therapeutic efficacy, particularly as precision medicine gains traction in neurology. The demand for reliable, non-invasive biomarkers is accelerating due to the rising global prevalence of neurodegenerative diseases, the limitations of clinical symptom-based diagnosis, and the need for objective measures in clinical trials. Advances in proteomics, genomics, and AI-driven data analysis are expanding the scope of biomarker discovery, though challenges remain in standardization, validation, and regulatory approval. The market is driven by increasing R&D investments, collaborations between pharmaceutical companies and diagnostic firms, and growing emphasis on early intervention strategies. However, high development costs, ethical concerns around genetic testing, and variability in biomarker sensitivity and specificity pose barriers to widespread adoption. North America and Europe dominate the market due to robust healthcare infrastructure, while Asia-Pacific shows rapid growth potential driven by aging populations and rising awareness. Emerging technologies like liquid biopsies and digital biomarkers are expected to reshape the landscape, offering scalable and cost-effective solutions for large-scale screening and personalized treatment approaches.

The global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size was estimated at USD 1678.28 million in 2024, exhibiting a CAGR of 8.75% during the forecast period.

This report provides a deep insight into the global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market in any manner.

Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

AbaStar MDx

Abbott Laboratories

Abiant

Acumen Pharmaceuticals

Alseres Pharmaceuticals

Athena Diagnostics

Banyan Biomarkers

Bio-Rad Laboratories

Diagenic ASA

Immunarray Pvt

Myriad RBM

Proteome Sciences

ProteoSys AG

Psynova Neurotech

Qiagen

Quanterix Corporation

Thermo Fisher Scientific

Market Segmentation (by Type)

Genome

Proteome

Market Segmentation (by Application)

Hospital Laboratories

Research Organizations

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market

Overview of the regional outlook of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market:

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

Table of Contents

171 Pages
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
1.2 Key Market Segments
1.2.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Segment by Type
1.2.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Overview
2.1 Global Market Overview
2.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Competitive Landscape
3.1 Company Assessment Quadrant
3.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Life Cycle
3.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Manufacturers (2020-2025)
3.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Manufacturers (2020-2025)
3.5 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Competitive Situation and Trends
3.8.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Concentration Rate
3.8.2 Global 5 and 10 Largest Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Industry Chain Analysis
4.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions and Their Impacts to Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market
5.7 ESG Ratings of Leading Companies
6 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Type (2020-2025)
6.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Market Share by Type (2020-2025)
6.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price by Type (2020-2025)
7 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Sales by Application (2020-2025)
7.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) by Application (2020-2025)
7.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Growth Rate by Application (2020-2025)
8 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Sales by Region
8.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region
8.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Market Share by Region
8.3 North America
8.3.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
8.3.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
8.4.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.5.2 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
8.6.2 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.7.2 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Production by Region
9.1 Global Production of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Region(2020-2025)
9.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Region (2020-2025)
9.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production
9.4.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.4.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production
9.5.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.5.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (2020-2025)
9.6.1 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.6.2 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (2020-2025)
9.7.1 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.7.2 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
10 Key Companies Profile
10.1 AbaStar MDx
10.1.1 AbaStar MDx Basic Information
10.1.2 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.1.3 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.1.4 AbaStar MDx Business Overview
10.1.5 AbaStar MDx SWOT Analysis
10.1.6 AbaStar MDx Recent Developments
10.2 Abbott Laboratories
10.2.1 Abbott Laboratories Basic Information
10.2.2 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.2.3 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.2.4 Abbott Laboratories Business Overview
10.2.5 Abbott Laboratories SWOT Analysis
10.2.6 Abbott Laboratories Recent Developments
10.3 Abiant
10.3.1 Abiant Basic Information
10.3.2 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.3.3 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.3.4 Abiant Business Overview
10.3.5 Abiant SWOT Analysis
10.3.6 Abiant Recent Developments
10.4 Acumen Pharmaceuticals
10.4.1 Acumen Pharmaceuticals Basic Information
10.4.2 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.4.3 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.4.4 Acumen Pharmaceuticals Business Overview
10.4.5 Acumen Pharmaceuticals Recent Developments
10.5 Alseres Pharmaceuticals
10.5.1 Alseres Pharmaceuticals Basic Information
10.5.2 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.5.3 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.5.4 Alseres Pharmaceuticals Business Overview
10.5.5 Alseres Pharmaceuticals Recent Developments
10.6 Athena Diagnostics
10.6.1 Athena Diagnostics Basic Information
10.6.2 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.6.3 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.6.4 Athena Diagnostics Business Overview
10.6.5 Athena Diagnostics Recent Developments
10.7 Banyan Biomarkers
10.7.1 Banyan Biomarkers Basic Information
10.7.2 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.7.3 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.7.4 Banyan Biomarkers Business Overview
10.7.5 Banyan Biomarkers Recent Developments
10.8 Bio-Rad Laboratories
10.8.1 Bio-Rad Laboratories Basic Information
10.8.2 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.8.3 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.8.4 Bio-Rad Laboratories Business Overview
10.8.5 Bio-Rad Laboratories Recent Developments
10.9 Diagenic ASA
10.9.1 Diagenic ASA Basic Information
10.9.2 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.9.3 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.9.4 Diagenic ASA Business Overview
10.9.5 Diagenic ASA Recent Developments
10.10 Immunarray Pvt
10.10.1 Immunarray Pvt Basic Information
10.10.2 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.10.3 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.10.4 Immunarray Pvt Business Overview
10.10.5 Immunarray Pvt Recent Developments
10.11 Myriad RBM
10.11.1 Myriad RBM Basic Information
10.11.2 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.11.3 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.11.4 Myriad RBM Business Overview
10.11.5 Myriad RBM Recent Developments
10.12 Proteome Sciences
10.12.1 Proteome Sciences Basic Information
10.12.2 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.12.3 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.12.4 Proteome Sciences Business Overview
10.12.5 Proteome Sciences Recent Developments
10.13 ProteoSys AG
10.13.1 ProteoSys AG Basic Information
10.13.2 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.13.3 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.13.4 ProteoSys AG Business Overview
10.13.5 ProteoSys AG Recent Developments
10.14 Psynova Neurotech
10.14.1 Psynova Neurotech Basic Information
10.14.2 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.14.3 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.14.4 Psynova Neurotech Business Overview
10.14.5 Psynova Neurotech Recent Developments
10.15 Qiagen
10.15.1 Qiagen Basic Information
10.15.2 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.15.3 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.15.4 Qiagen Business Overview
10.15.5 Qiagen Recent Developments
10.16 Quanterix Corporation
10.16.1 Quanterix Corporation Basic Information
10.16.2 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.16.3 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.16.4 Quanterix Corporation Business Overview
10.16.5 Quanterix Corporation Recent Developments
10.17 Thermo Fisher Scientific
10.17.1 Thermo Fisher Scientific Basic Information
10.17.2 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.17.3 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.17.4 Thermo Fisher Scientific Business Overview
10.17.5 Thermo Fisher Scientific Recent Developments
11 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Region
11.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast
11.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country
11.2.3 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Region
11.2.4 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Country
12 Forecast Market by Type and by Application (2026-2033)
12.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2026-2033)
12.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2026-2033)
12.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Application (2026-2033)
12.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) Forecast by Application
12.2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) Forecast by Application (2026-2033)
13 Conclusion and Key Findings
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.